Welcome to CDC stacks | TDF2 study of pre-exposure prophylaxis (PrEP) among heterosexual men and women in Botswana : key facts - 23283 | Stephen B. Thacker CDC Library collection
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
TDF2 study of pre-exposure prophylaxis (PrEP) among heterosexual men and women in Botswana : key facts
  • Published Date:
    8/26/11
  • Language:
    English
Filetype[PDF-98.02 KB]


Details:
  • Corporate Authors:
    Centers for Disease Control and Prevention (U.S.)
  • Description:
    Overview -- Trial design and study population -- Study results -- Adherence and risk behavior -- Safety and resistance -- Resources.

    Daily oral PrEP with a tablet containing tenofovir disoproxil fumarate and emtricitabine (TDF/FTC, known by the brand name Truvada®) was found to reduce the risk of acquiring HIV infection by roughly 63 percent in the study population overall.

    In addition, researchers conducted a separate analysis to better understand the level of efficacy among trial participants believed to be taking study medications. This analysis excludes any HIV infections that occurred more than 30 days1 after a participant’s last reported drug dose, because those individuals could not have been taking study pills at the time of infection. These results indicate that TDF/FTC reduced the risk of HIV infection by 78 percent.

  • Place as Subject:
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like: